Study Targets Solid Tumor Cancer Patients with Poor Prognosis or Limited Treatment Options
August 21, 2013
As modern cancer treatments become more personalized, Cleveland Clinic is now offering select cancer patients the opportunity to have their tumors analyzed for genetic mutations that could influence their treatments.
For the next year, cancer patients with one of 15 specific solid tumors with historically poor prognosis or limited treatment options will have the opportunity to participate in a study where their tissue samples will be sent for targeted genetic sequencing to Foundation Medicine, a molecular information company specializing in comprehensive genomic analysis of tumors.
Participating patients’ tissue samples will be analyzed with a test that examines more than 230 cancer-related genes to provide information on the tumor’s genomic composition and identifies genomic alterations that could guide treatment. Once the analysis is complete, an independent team of Taussig Cancer Institute oncologists will review the results and recommend a personalized treatment plan which could include chemotherapy, radiation, targeted therapies and/or participation in a clinical trial that may benefit the patient.
“Personalized medicine is changing the way we treat cancer,” says Davendra Sohal, MD, MPH, staff physician in the department of Solid Tumor Oncology at Cleveland Clinic’s Taussig Cancer Institute and principal investigator. “Knowing the specific genomic composition of a tumor may allow us to create precise, individual treatment plans for patients rather than relying on standard treatments that may be ineffective and may result in unnecessary treatment costs.”
Since its inception, Cleveland Clinic has been at the forefront of cancer breakthroughs. Cleveland Clinic physicians and scientists have developed new surgical techniques, discovered new treatments and uncovered new information about cancer cells that have changed the way patients are screened, diagnosed and treated. Advancements in cancer genomics are the next step.
“This is a very exciting time in cancer research,” says Brian J. Bolwell, MD, FACP, chairman of Cleveland Clinic’s Taussig Cancer Institute. “This type of personalized cancer medicine can help patients with recurrent cancers or with cancers that do not respond well to current treatment protocols. Through this collaboration, we can give patients more treatment options than ever before.”
For more information on Cleveland Clinic cancer services, call the Cancer Answer Line at 1.866.223.8100 or visit http://clevelandclinic.org/cancer.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, currently under construction, Cleveland Clinic Abu Dhabi. In 2012, there were 5.1 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. Visit us at http://www.clevelandclinic.org. Follow us at http://www.twitter.com/ClevelandClinic.
Stephanie Jansky, 216.636.5869, firstname.lastname@example.org